Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cellular immunotherapy for cancer. Past, present, future

Cellular immunotherapy for cancer. Past, present, future editorial memo (2012) 5:81–84 DOI 10.1007/s12254-012-0023-2 Cellular immunotherapy for cancer. Past, present, future Alexandros Spyridonidis Received: 5 March 2012 / Accepted: 22 May 2012 / Published online: 19 June 2012 © Springer-Verlag Wien 2012 Alexandros Spyridonidis The first steps towards cellular immunotherapy (GvHD) compared with those free of GvHD, induction for cancer of remission in patients after withdrawal of immunosup- pression, and higher relapse rates in recipients receiving The notion that immunocompetent cells, contained wit- T-cell depleted grafts compared with unmanipulated hin adult bone marrow or peripheral blood, are capable grafts [6–8]. The first patient to receive adoptive T-cell of mediating an antitumor effect was first validated expe- immunotherapy was a boy with acute lymphoblastic rimentally in 1957 by Barnes [1]. In these experiments, leukemia (ALL) who relapsed after bone marrow trans- leukemic animals that were lethally irradiated and plantation and obtained a sustained complete remission reconstituted with allogeneic marrow had a lower tumor of his disease by receiving multiple transfusions of lym- burden following transplantation than similarly treated phocytes from his sister, the original bone marrow donor animals that were reconstituted with syngeneic marrow. [9]. Kolb et al. [10] validated the efficacy of this appro- This immunologic antitumor effect http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Cellular immunotherapy for cancer. Past, present, future

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/cellular-immunotherapy-for-cancer-past-present-future-o7JBmkhmVS
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0023-2
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2012) 5:81–84 DOI 10.1007/s12254-012-0023-2 Cellular immunotherapy for cancer. Past, present, future Alexandros Spyridonidis Received: 5 March 2012 / Accepted: 22 May 2012 / Published online: 19 June 2012 © Springer-Verlag Wien 2012 Alexandros Spyridonidis The first steps towards cellular immunotherapy (GvHD) compared with those free of GvHD, induction for cancer of remission in patients after withdrawal of immunosup- pression, and higher relapse rates in recipients receiving The notion that immunocompetent cells, contained wit- T-cell depleted grafts compared with unmanipulated hin adult bone marrow or peripheral blood, are capable grafts [6–8]. The first patient to receive adoptive T-cell of mediating an antitumor effect was first validated expe- immunotherapy was a boy with acute lymphoblastic rimentally in 1957 by Barnes [1]. In these experiments, leukemia (ALL) who relapsed after bone marrow trans- leukemic animals that were lethally irradiated and plantation and obtained a sustained complete remission reconstituted with allogeneic marrow had a lower tumor of his disease by receiving multiple transfusions of lym- burden following transplantation than similarly treated phocytes from his sister, the original bone marrow donor animals that were reconstituted with syngeneic marrow. [9]. Kolb et al. [10] validated the efficacy of this appro- This immunologic antitumor effect

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 19, 2012

References

  • Treatment of murine leukaemia with x-rays and homologous bone marrow. II
    Barnes, DW; Loutit, JF
  • Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia
    Bortin, MM; Rimm, AA; Saltzstein, EC
  • Adoptive immunotherapy of acute leukemia: experimental and clinical results
    Mathe, G; Amiel, JL; Schwarzenberg, L
  • Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions
    Schwarzenberg, L; Mathe, G; Schneider, M
  • Immunotherapy of malignant disease
    Nadler, SH; Moore, GE
  • Graft-versus-leukemia reactions after bone marrow transplantation
    Horowitz, MM; Gale, RP; Sondel, PM
  • Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation
    Weiden, PL; Sullivan, KM; Flournoy, N
  • Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
    Goldman, JM; Gale, RP; Horowitz, MM
  • Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes
    Slavin, S; Naparstek, E; Nagler, A
  • Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
    Kolb, HJ; Mittermuller, J; Clemm, C
  • Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes
    Faber, LM; Van Der Hoeven, J; Goulmy, E
  • Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Dudley, ME; Yang, JC; Sherry, R
  • Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
    Pule, MA; Savoldo, B; Myers, GD
  • Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
    Bollard, CM; Gottschalk, S; Leen, AM
  • Cancer regression in patients after transfer of genetically engineered lymphocytes
    Morgan, RA; Dudley, ME; Wunderlich, JR
  • Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
    Riddell, SR; Watanabe, KS; Goodrich, JM
  • Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
    Hanley, PJ; Cruz, CR; Savoldo, B
  • Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
    Heslop, HE; Slobod, KS; Pule, MA
  • Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
    Rosenberg, SA; Aebersold, P; Cornetta, K
  • The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
    Cheever, MA; Allison, JP; Ferris, AS
  • Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma
    Gerdemann, U; Katari, U; Christin, AS
  • Principles for adoptive T cell therapy of human viral diseases
    Riddell, SR; Greenberg, PD
  • Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
    Berger, C; Jensen, MC; Lansdorp, PM
  • A human memory T cell subset with stem cell-like properties
    Gattinoni, L; Lugli, E; Ji, Y
  • Th17 cells are long lived and retain a stem cell-like molecular signature
    Muranski, P; Borman, ZA; Kerkar, SP
  • Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Dudley, ME; Wunderlich, JR; Yang, JC
  • Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity
    Bollard, CM; Rossig, C; Calonge, MJ
  • Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    Porter, DL; Levine, BL; Kalos, M
  • Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)
    Vera, JF; Brenner, LJ; Gerdemann, U
  • Defining the critical hurdles in cancer immunotherapy
    Fox, BA; Schendel, DJ; Butterfield, LH